Breaks Categories: Stock Spotlights

FridayAug 14, 2026 1:38 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial Case for GelrinC in Multi-Billion Knee Cartilage Repair Market

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article highlighting the potential of its GelrinC cell-free hydrogel implant to address longstanding challenges in focal knee injuries through an off-the-shelf treatment designed to simplify surgical workflows, support faster recovery and promote durable tissue regeneration. The company recently received European regulatory approval for a next-generation, solvent-free manufacturing process that increases production yield by approximately 400%, supporting greater scalability and lower production costs. Regentis is also advancing surgeon training and European commercialization while progressing its pivotal U.S. Phase III SAGE trial, which is more than 50% enrolled. GelrinC’s combination of procedural simplicity, clinical…

Continue Reading

FridayAug 07, 2026 2:59 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory and commercial milestones amid growing interest in regenerative orthopedic solutions. GelrinC is an off-the-shelf, cell-free implant designed for a streamlined, single-step procedure that supports cartilage regeneration without the cell harvesting and laboratory processing required by some alternative approaches. Regentis is continuing enrollment in its U.S. clinical study, preparing for a potential FDA Premarket Approval submission, expanding commercialization efforts in Europe following CE Mark approval, and optimizing manufacturing for scalability and consistency. To view the full article, visit https://ibn.fm/mVCsB About Regentis Biomaterials Ltd. Regentis Biomaterials is a…

Continue Reading

FridayAug 07, 2026 2:16 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Two-Pronged Approach to Neurological Health

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, is developing a two-pronged strategy addressing neurological health through its investigational multiple sclerosis therapy Lucid-MS and its proprietary dietary supplement unbuzzd. Lucid-MS is designed to target PAD2, an enzyme associated with myelin degradation, with the goal of protecting and potentially restoring the myelin sheath rather than primarily modulating the immune system. The company submitted an IND application to the FDA for a Phase 2 trial and is supporting development through an imaging collaboration…

Continue Reading

FridayAug 07, 2026 1:21 pm

BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Builds Strategic Position in Antibody Therapeutics Market

VERAXA Biotech (NASDAQ: VRXA) is developing next-generation antibody therapeutics across antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), two areas that continue to attract significant pharmaceutical investment. A recent article highlights major transactions to illustrate how differentiated antibody-engineering platforms can attract substantial financial commitments even before clinical development reaches advanced stages. VERAXA’s proprietary BiTAC platform supports a pipeline that includes bispecific ADCs, T-cell engagers and engineered antibody formats, potentially creating opportunities for future platform partnerships, licensing agreements or asset-level transactions. To view the full article, visit https://ibn.fm/sMjlp About VERAXA Biotech AG VERAXA is building a premier engine for the discovery and development of…

Continue Reading

WednesdayAug 05, 2026 1:17 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Combines Targeted Cancer Therapy, Nanotechnology and AI

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is pursuing an integrated approach to cancer drug development that combines three emerging areas: PNKP-targeted DNA damage response (“DDR”) inhibition, nanoparticle drug delivery and artificial intelligence. Its lead candidate, ONC010, pairs a PNKP inhibitor with a polymer micelle carrier intended to improve drug solubility, tumor accumulation and tolerability, while the company’s Inka Health subsidiary is developing the SynoGraph causal AI platform to support patient selection, clinical trial design and evidence generation. The company is advancing ONC010 through preclinical, manufacturing and IND-enabling activities, with plans…

Continue Reading

WednesdayAug 05, 2026 12:55 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Advances Telehealth Position Through Technology, Vertical Integration

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its positioning in the growing telehealth and healthcare markets through strategic investments, vertical integration and proprietary technology. Through subsidiaries such as DOConsultations LLC and Las Villas Health Care Inc., the company provides online and brick-and-mortar telehealth services focused on wellness and direct-to-patient delivery, while also targeting the expanding peptide therapy market. ETST’s in-house IT capabilities and custom technology infrastructure are designed to provide a competitive advantage by improving operational efficiency and margins across its divisions. As the company continues expanding its technology and healthcare offerings, its integrated platform…

Continue Reading

FridayJul 31, 2026 3:53 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed its efforts to advance GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform, and the company’s broader mission to establish a new standard of care in cartilage repair. “Regentis is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather than simply manage symptoms. With cartilage defects affecting hundreds of thousands of patients each year and contributing to pain, reduced mobility, and degenerative joint disease, the company is targeting one of orthopedic medicine’s largest unmet needs,” reads the article. “GelrinC’s commercial potential is rooted in…

Continue Reading

FridayJul 31, 2026 3:44 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot MS imaging study with Massachusetts General Hospital, with preliminary PET imaging data showing encouraging signals in acute MS lesions. The novel imaging technique is designed to distinguish demyelinated nerve fibers that may still be viable from permanent nerve damage, potentially offering a more precise way to measure myelin loss and repair. “These findings are directly relevant to Lucid-MS, the company’s investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which…

Continue Reading

ThursdayJul 30, 2026 12:23 pm

BioMedNewsBreaks — Earth Science Tech Inc.’s (ETST) Vertical Integration Drives Revenue Growth, Product Expansion

Earth Science Tech (OTC: ETST) is leveraging a diversified, vertically integrated business model spanning pharmaceuticals, telemedicine, retail and real estate. Through subsidiaries including Peak Curative, RxCompound and Mister Meds, the company connects telemedicine consultations, compounding pharmacies and medication fulfillment within an end-to-end healthcare ecosystem. Its MOCTeledoc platform also provides B2B technology and clinical staffing solutions, allowing ETST to generate revenue by supporting other digital health companies while expanding its own reach. The integrated model supports product development and diversification, contributing to fiscal 2026 revenue growth of 8%, alongside increases in gross profit and net income. To view the full article, visit https://ibn.fm/I1F0R…

Continue Reading

WednesdayJul 29, 2026 3:54 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Targets $3 Billion Cartilage Repair Market with Cell-Free Gelrin C

Regentis Biomaterials (NYSE American: RGNT) is positioning its Gelrin C hydrogel as a practical regenerative medicine solution for cartilage damage that could help address the substantial clinical and economic burden associated with knee osteoarthritis (“OA”). Gelrin C is a cell-free, off-the-shelf hydrogel administered in a single 10-minute procedure, designed to support cartilage regeneration while avoiding the multiple surgeries, specialized laboratory processing and higher costs associated with some cell-based therapies. With approximately 470,000 knee cartilage repair procedures performed annually in the U.S., representing an estimated $3 billion market, the company believes Gelrin C could offer a more scalable approach that fits existing surgical…

Continue Reading